Tezosentan in Pulmonary Arterial Hypertension

Summary

Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines

Timeline

Start

2010-08

Primary completion

2010-11

Completion

2011-09

Outcome

Outcome not reported

Stopped (Enrollment): “Due to slow recruitment, the study was prematurely discontinued”

Drugs

Indications